Navigation Links
Arbel Medical has Completed a $4.5 million Round of Capital Raising led by Giza Venture Capital Fund
Date:7/17/2008

YOKNEAM, Israel, July 17 /PRNewswire/ -- Arbel Medical, an Israeli start-up developing the next generation of medical equipment for removing tumors by freezing (cryotherapy), has completed raising $4.5 million of capital in its second round, led by the Giza Venture Capital fund.

The Docor International investment company, of the Van Leer group, has invested $1 million, joining the other Arbel investors who include Giza Venture Capital, Ofer High Tech, the Bridge Investment Fund from the USA, TRD and Fattal.

Dr Alon Dumanis, CEO of Docor, will be appointed as a member of the Board of Directors of Arbel Medical.

Arbel Medical works in the field of minimal-invasive treatments. The company is developing next generation medical devices for removing tumors by freezing (cryotherapy). Cryotherapy is currently considered as the most promising minimally invasive technique for removing tumors, a market that, according to MedMarket Diligence, is expected to grow at a rate of 30% a year in the coming decade. Arbel Medical brings promising news to women's health treatments, a market worth billions of dollars. Quick and effective treatment using Arbel's innovative device can even be carried out in clinics outside hospitals.

It should be noted that Arbel Medical was chosen as one of the three most promising start-ups in Israel in 2007 by the Export Institute, the Israel Life Sciences Institute (ILSI) and LSA.

Didier Toubia, Co-Founder of Arbel Medical, said that "the current round of capital raising provides the company important leverage to accelerate and expand its clinical trials overseas, establish itself in the American market, and launch its first product onto this market in 2009."

Elka Nir, a Partner in Giza and Chairperson of the Board of Directors of Arbel Medical, said: "Arbel is developing an innovative solution that meets a considerable need in the market and will provide a substitute for many of the surgical operations carried out in this field. We've been impressed by Arbel's achievements, including FDA approval, and are certain that Giza's global connections, experience and capabilities in the field of medical equipment will help the company fulfill its business vision.

We welcome Docor International joining the group of investors and the board of Directors, and are sure that they will make a great contribution to the Company."

Dr Alon Dumanis, CEO of Docor International, says: "After examining the company's capabilities and the market potential, it is our impression that Arbel's product is based on a ground-breaking technology that has already created considerable interest in the medical community. We are delighted to add Arbel Medical to Docor's portfolio, and intend to help the company meet its business goals with our experience and know-how in the field of life sciences."

About Arbel Medical

Arbel Medical, established in 2006, is active in the field of minimal-invasive treatments. The company is developing next generation medical devices for removing tumors by freezing (cryotherapy).

Among Arbel Medical's investors are Giza Venture Capital, which led the last capital raising round, the Ofer High Tech Group, the US-based Bridge Investment Fund, Docor International, TRD and Fattal.

About Docor International B.V

A leading investment group, Docor International B.V is part of the Van Leer Group Foundation. Docor invests in advanced technology-based companies with an Israeli presence, that make a significant contribution to the local economy. It focuses on companies in the life sciences, information technology and on industrial sectors with innovative technologies.

About Giza Venture Capital

Giza Venture Capital was established in 1992 and was one of the first Israeli investors specializing in early stage and seed investment. Giza manages around $500 million in four funds, and has invested in 87 companies with 32 exits to date.

Giza focuses in the fields of communications, semi-conductors, software, IT, internet, new media, and life sciences, and has offices in Tel Aviv and Singapore.

For additional information: http://www.arbel-medical.com or Didier Toubia, Co-Founder of Arbel Medical, toubia@arbel-medical.com. tel: +972-49090000


'/>"/>
SOURCE Arbel Medical
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
2. Saving Certified Continuing Medical Education (CME)
3. ATS Medical Confirms Excellent Durability of the ATS Open Pivot Mechanical Heart Valve
4. NorthPoint Domain and Boston Medical Center Partner to Apply Advanced Patient Engagement Instruments to Pioneering Cardiac Robotic Surgery Program
5. RADI Medical Systems Launches Next Generation PressureWire(R) Certus
6. BioElectronics ActiPatch(TM) Product Chosen as One of 9 Medical Breakthroughs That May Change Your Life
7. Medical Ventures Becomes Neovasc with Two Corporate Acquisitions and $8.3 Million Financing
8. Oridion Wins 2008 Manufacturers Partnership Award From Independent Medical Distributors Association
9. Polymathic Analytical Labs Debuts at World's Largest Medical Design & Manufacturing Exhibition
10. Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point
11. Website and Blog Increase Placement for Medical Sales Recruiter - Providing Sales Winners Calling on the Hospital, Lab and Physician Call Point
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... 2017 AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ... and commercialization of innovative therapies for the treatment ... Food and Drug Administration (FDA) has accepted the ... for DSUVIA™ (formerly ARX-04) (sufentanil sublingual tablet, 30 ... acute pain in a medically supervised setting. The ...
(Date:2/27/2017)... FRANCISCO , Feb. 27, 2017 Fluxion ... Spain has been appointed as a ... System. The IsoFlux system will be used in Genetracer ... relevant to lung and colon cancer, with plans to ... The laboratory is utilizing Fluxion,s IsoFlux System to isolate, ...
(Date:2/26/2017)... ... February 26, 2017 , ... Rob Lowe is a well recognized television personality, ... "Informed," focuses on issues that are important to the American public and important to ... has been a hot topic around the world for a few years. , The ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... Delpor, Inc. ... $224K grant from the National Institute of Mental Health (NIMH) for the further advancement ... Delpor’s PROZOR technology and is expected to deliver therapeutic levels of olanzapine ...
Breaking Biology Technology:
(Date:2/13/2017)... Former 9/11 Commission border counsel and Special Counsel to ... of Identity Strategy Partners, LLP, today releases the following ... Protecting the Nation From Foreign Terrorist Entry Into the ... Trump,s ,Travel Ban, Executive Order gains more notoriety and ... ban, it is important that our national discourse regain ...
(Date:2/8/2017)... -- Report Highlights ... The global synthetic-biology market reached nearly $3.9 billion ... at a compound annual growth rate (CAGR) of 24.0% through ... markets for synthetic biology. - Analyses of global market trends, ... compound annual growth rates (CAGRs) through 2021. - Coverage of ...
(Date:2/7/2017)... LONG BEACH, New York , February 7, 2017 ... formerly known as ID Global Solutions Corporation [OTC: IDGS], ... identification, identity management and electronic transaction processing services, is ... a reorganization of the Company. Effective January ... Chairman of the Board of Directors, CEO and President. ...
Breaking Biology News(10 mins):